Abstract 132P
Background
Oncogenic mutation p53(Y220C) is the ninth most common mutation of the p53 protein. Mutation Y220C creates an expanded surface pocket in the DNA-binding domain of p53, due to which the protein is rapidly denatured under physiological conditions. This also negatively affects the effectiveness of p53-dependent signaling and leads to tumor development. In this work, new indazole derivatives were investigated as modulators of mutant p53 activity. We found that the compounds studied were able to initiate an anti-tumor cellular response by activating mutant p53(Y220C).
Methods
Immunocytochemical analysis (ICC) was performed to test the hypothesis that the mutant protein p53(Y220C) can restore its native-like conformation and get reactivated upon interaction with the compounds. The degree of p53 activation was evaluated, and the protein localization in HUH7 p53(Y220C) human hepatocarcinoma cells was determined upon treatment with indazole derivatives.
Results
During the immunocytochemical analysis, images obtained were analyzed using the ImageJ software, and the values of p53 signal intensity were calculated. We found that in comparison with control untreated cells, in samples treated with indazole derivatives increased in levels of p53 were observed mainly in the nucleus, which indicates its activation.
Conclusions
The results of the immunocytochemical analysis demonstrated that indazole derivatives specifically activate mutant p53(Y220C) protein. The compounds represent a promising basis for the development of selective activators not only for Y220C, but also for other mutant forms of p53. The work was funded by grant from the Russian Science Foundation 22-24-20034 and supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030).
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
The work was funded by grant from the Russian Science Foundation 22-24-20034 and supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
30P - Role of microRNA and CDKN2A/p16INK4a expression in the prognostication of oral squamous cell carcinoma
Presenter: Olha Burtyn
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Identification of proteins associated with mRNA processing and maturation by quantitative proteomic analysis in Indian cervical cancer patients
Presenter: Amrita Mukherjee
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients
Presenter: Katerina Dvorakova
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Unraveling the mechanisms of cisplatin resistance in bladder organoid by single cell RNA sequencing
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy
Presenter: Jelena Dinić
Session: Cocktail & Poster Display session
Resources:
Abstract
35P - Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells
Presenter: Lee Ellis
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Comparison of pelitinib, tepotinib or docetaxel efficacy according to the copy number or gene alteration status of EGFR, MET, HRAS, KRAS and NRAS genes
Presenter: Dae Young Zang
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - NET-mediated radio-resistance in early-stage non-small cell lung cancer
Presenter: Malcolm Ryan
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - The use of antibiotics or proton pump inhibitors and the response to intravesical Bacillus Calmette Guérin therapy in non-muscle-invasive bladder cancer
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - YAP1 promotes sorafenib resistance by activation of TGFβ signaling pathway
Presenter: Chit Lai Chee
Session: Cocktail & Poster Display session
Resources:
Abstract